menu
    • menu
    [{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Sovateltide","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharmazz \/ Not Applicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Sovateltide","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharmazz \/ Not Applicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Sovateltide","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharmazz \/ Not Applicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Sovateltide","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharmazz \/ Not Applicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Sovateltide","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous injection","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharmazz \/ Not Applicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Sovateltide","moa":"ETB receptor","graph1":"Neurology","graph2":"Approved","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/ Not Applicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Sovateltide","moa":"ETB receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharmazz \/ Not Applicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Sovateltide","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/ Not Applicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Sovateltide","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/ Not Applicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Sovateltide","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/ Not Applicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"Sovateltide","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Sovateltide","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharmazz \/ Not Applicable"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Peptide","year":"2024","type":"Financing","leadProduct":"Sovateltide","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Pharmazz","amount2":0.02,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Pharmazz \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"14","companyTruncated":"Pharmazz \/ Sun Pharmaceutical Industries Limited"}]

    Find Clinical Drug Pipeline Developments & Deals for Sovateltide

    Menu

    Sovateltide

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Pharmazz

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Pharmazz

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sovateltide

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Sun Pharmaceutical Industries Limited

                            Deal Size : $15.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Pharmazz and Sun Pharma Partner for $15 Million Investment in Pharmazz

                            Details : The financing will support completion of Pharmazz's pivotal Phase 3 study for Tyvalzi (sovateltide) to treat patients with acute cerebral ischemic stroke.

                            Brand Name : Tyvalzi

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            August 21, 2024

                            Lead Product(s) : Sovateltide

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Sun Pharmaceutical Industries Limited

                            Deal Size : $15.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pharmazz

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Pharmazz

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sovateltide

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            A Special Protocol Assessment Agreement Reached with the U.S. Food and Drug Administration for Phase 3 Clinica...

                            Details : Tycamzzi (Sovateltide), is a first-in-class drug and endothelin-B receptor agonist that increases blood flow and inhibits apoptosis, which is investigated for the treatment of acute cerebral ischemic stroke patients.

                            Brand Name : Tycamzzi

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            October 02, 2023

                            Lead Product(s) : Sovateltide

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Pharmazz

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Pharmazz

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sovateltide

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Sun Pharmaceutical Industries Limited

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Pharmazz Inc. and Sun Pharma Enter into Licensing Agreement for Introducing Tyvalzi™ (sovateltide) in India

                            Details : Underf the agreement, Sun Pharma is granted rights for marketing Sovateltide in India under the brand name Tyvalzi, a selective endothelin B receptor agonist and a new first-in-class drug recently approved for treating cerebral ischemic stroke.

                            Brand Name : Tyvalzi

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            September 13, 2023

                            Lead Product(s) : Sovateltide

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Sun Pharmaceutical Industries Limited

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Pharmazz

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Pharmazz

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sovateltide

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pharmazz, Inc. Announces Marketing Approval of Sovateltide in India for Acute Cerebral Ischemic Stroke Patient...

                            Details : Tycamzzi, a first-in-class drug and endothelin-B receptor agonist that increases blood flow and inhibits apoptosis, receives marketing approval in India for the treatment of acute cerebral ischemic stroke. Sovateltide is in Phase 3 trial in US for the sa...

                            Brand Name : Tycamzzi

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            May 31, 2023

                            Lead Product(s) : Sovateltide

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Pharmazz

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Pharmazz

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sovateltide

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pharmazz, Inc. Announces US FDA Clearance for a Phase III Clinical Trial of Sovateltide (PMZ-1620) in Acute Ce...

                            Details : Tycamzzi (sovateltide) is a highly selective endothelin-B receptor agonist, having the potential to be a neuronal progenitor cell therapeutics with anti-apoptotic activity that improves cerebral blood flow and neurological outcome in acute cerebral ische...

                            Brand Name : Tycamzzi

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            February 13, 2023

                            Lead Product(s) : Sovateltide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Pharmazz

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Pharmazz

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sovateltide

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Clinical Phase III Trial Results Demonstrating Sovateltide's Efficacy to Treat Acute Cerebral Ischemic Stroke ...

                            Details : Results of this trial shows highly encouraged regarding the potential of Tycamzzi (sovateltide) to be the first therapeutic since tPA to demonstrate a positive impact on patients suffering from acute ischemic stroke.

                            Brand Name : Tycamzzi

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            February 10, 2023

                            Lead Product(s) : Sovateltide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Pharmazz

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Pharmazz

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sovateltide

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pharmazz Inc. Presents Positive Results of Phase III Clinical Trial Demonstrating Sovateltide’s Efficacy as ...

                            Details : PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke pa...

                            Brand Name : PMZ-1620

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            October 31, 2022

                            Lead Product(s) : Sovateltide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Pharmazz

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Pharmazz

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sovateltide

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pharmazz Inc. Announces Two Presentations on Sovateltide as a Treatment for Acute Ischemic Stroke at the 14th ...

                            Details : Tycamzzi (sovateltide), an endothelin-B receptor agonist, has been previously shown to increase cerebral blood flow, have anti-apoptotic activity and produce neurovascular remodeling when administered IV following acute cerebral ischemic stroke in rats.

                            Brand Name : Tycamzzi

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            October 26, 2022

                            Lead Product(s) : Sovateltide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Pharmazz

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Pharmazz

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sovateltide

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pharmazz Inc. Announces Indian Central Drugs Standard Control Organization (CDSCO) Clearance of IND to Conduct...

                            Details : PMZ-1620 (sovateltide) is endothelin-B receptor agonist that increases blood flow, shows anti-apoptotic activity, protects neural mitochondria, and produces neurovascular remodeling. Sovateltide is undergoing MA review by CDSCO for acute cerebral ischemi...

                            Brand Name : PMZ-1620

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            August 29, 2022

                            Lead Product(s) : Sovateltide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Pharmazz

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Pharmazz

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sovateltide

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pharmazz Inc. Submits Investigational New Drug Application to India Central Drugs Standard Control Organizatio...

                            Details : PMZ-1620 having Sovateltide as API, is the Company’s endothelin-B receptor agonist that is also in a Phase III trial for the treatment of cerebral ischemic stroke. In clinical trials, subjects will receive either three intravenous doses of sovateltide,...

                            Brand Name : PMZ-1620

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            February 03, 2022

                            Lead Product(s) : Sovateltide

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth